Premium
Thiethylperazine‐induced parkinsonism: in vivo demonstration of dopamine D 2 receptors blockade
Author(s) -
Briani C.,
Cagnin A.,
Chierichetti F.,
Tiberio M.,
Battistin L.,
Pizzolato G.
Publication year - 2004
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2004.00844.x
Subject(s) - parkinsonism , medicine , dopamine receptor , basal ganglia , dopamine , akathisia , tardive dyskinesia , dystonia , dyskinesia , pharmacology , neuroscience , anesthesia , psychology , psychiatry , central nervous system , schizophrenia (object oriented programming) , parkinson's disease , disease , antipsychotic
Thiethylperazine (Torecan ® ) is a piperazine phenothiazine employed to relieve vertigo. Its use may be associated with extrapyramidal side effects (dystonia, akathisia, tardive dyskinesia) (Sulkava, 1984), but parkinsonism has rarely been described. We describe a woman who, 1 month after the onset of thiethylperazine treatment, developed parkinsonism that disappeared 2 months after withdrawal of the drug. However, cerebral single‐photon emission computed tomography (SPECT) with the dopamine (DA) D 2 receptors ligand 123 I‐iodobenzamide ( 123 I‐IBZM) revealed a persistent reduced DA D 2 receptors activity (by 45%) in the basal ganglia (BG), which may be clinically not effective.